Table 4

SRM with 95% CI for all measures at 6 weeks

GroupSRM (95% CI)
Clinical and laboratory parameters
 DAS28Placebo−0.16 (−0.73 to 0.40)
Etanercept−2.16 (−2.61 to −1.71)
 HAQ scorePlacebo0.10 (−0.46 to 0.66)
Etanercept−0.65 (−1.10 to −0.20)
 CRP (mg/dl)Placebo0.28 (−0.28 to 0.85)
Etanercept−0.79 (−1.24 to −0.34)
 ESR (mm/h)Placebo0.32 (−0.24 to 0.88)
Etanercept−0.86 (−1.31 to −0.41)
MRI parameters
 RAMRIS synovitis (0–21)Placebo−0.46 (−1.03 to 0.10)
Etanercept−0.90 (−1.35 to −0.45)
 RAMRIS bone marrow oedema (0−69)Placebo0.0 (−0.56 to 0.56)
Etanercept−0.41 (−0.86 to 0.03)
 RAMRIS erosion (0−230)Placebo0.16 (−0.39 to 0.73)
Etanercept−0.23 (−0.68 to 0.21)
 RAMRIS total (0−320)Placebo−0.05 (−0.62 to 0.50)
Etanercept−0.51 (−0.96 to −0.06)
 Tenosynovitis (0−26)Placebo0.18 (−0.38 to 0.74)
Etanercept−0.39 (−0.84 to 0.05)
 MRI total inflammation (synovitis + tenosynovitis + bone marrow oedema) (0−116)Placebo−0.06 (−0.63 to 0.50)
Etanercept−0.71 (−1.16 to −0.27)
 MRI inflammation (synovitis + tenosynovitis) (0−47)Placebo−0.12 (−0.68 to 0.44)
Etanercept−0.71 (−1.16 to −0.27)
  • CRP, C-reactive protein; DAS28, disease activity score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score; SRM, standardised response mean.